Long-term efficacy and toxicity of ciclosporin A in combination with methotrexate in poor prognosis rheumatoid arthritis: Table 1
| Autor: | Andrew K. Brown, Paul Emery, Susanna Proudman, Victoria Bejarano, Maya H Buch, P.G. Conaghan |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Poor prognosis
medicine.medical_specialty Combination therapy business.industry Immunology Pharmacology medicine.disease Ciclosporin Gastroenterology General Biochemistry Genetics and Molecular Biology Rheumatology Sulfasalazine Rheumatoid arthritis Internal medicine Toxicity medicine Immunology and Allergy Methotrexate business Antirheumatic drugs medicine.drug |
| Zdroj: | Annals of the Rheumatic Diseases. 68:761-763 |
| ISSN: | 1468-2060 0003-4967 |
| Popis: | Whereas the optimum therapy for early rheumatoid arthritis (RA) has not been established, there is still interest in combination therapy with existing disease-modifying antirheumatic drugs, due to the cost and toxicity of biological agents. We previously reported a 24-month open-label, randomised study comparing a methotrexate and ciclosporin A combination with sulfasalazine monotherapy in 82 early, poor-prognosis RA patients (n = 40 combination, n = 42 sulfasalazine).1 In the combination arm, first ciclosporin A then methotrexate doses were optimised. After 24 months all patients were treated according to standard clinical care. The aim of this report is to present long-term efficacy and toxicity data. At 12 months there was no difference in … |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|